Literature DB >> 797501

Pharmacokinetics of the penicillins in man.

M Barza, L Weinstein.   

Abstract

The purpose of this article is to review and summarise those aspects of the pharmacokinetic behaviour of the penicillins that may be of particular interest to the clinician. While these antibiotics differ markedly in their acid stability and oral absorption, misleading inferences may be drawn from simple inspection of the maximal serum concentrations produced by a given dose administered orally. A more accurate picture emerges when serum protein binding and intrinsic activity of the drugs are taken into account. All of the penicillins are readily and actively secreted by the renal tubles and most are eliminated, almost completely unchanged, in the urine. The majority are excreted in small quantities in the bile, but this is a major route for elimination of nafcillin from the body. Distribution of the penicillins in 'non-specialised' sites is excellent. In contrast, penetration of the central nevous system and eye are poor, and of the prostate, minimal. Inflammation reduces the barries to penetration of these areas. However, quantitative data related to this phenomenon in man are few. Probenecid actively competes with the 'export' pump of the meninges and renal tubular cells. This results in an increase in concentrations of the penicillins in the blood and cerebrospinal fluid. The effect of this agent on active secretion of these antibiotics from the eye and biliary tract is minimal. While elimination of the penicillins from the body takes place largely via renal excretion, penicillin V and oxacillin are extensively degraded as well. In contrast to the situation with respect to 'natural' and 'broad-spectrum' penicillins, the serum half-life of the isoxazolyl congeners and nafcillin is only minimally prolonged in the presence of renal failure. These agents are only weakly haemodialyzable, while the other penicillins are rapidly removed from the circulation by this procedure.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 797501     DOI: 10.2165/00003088-197601040-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  73 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

2.  Comparison of antibiotic activity in sera after the administration of three different penicillins.

Authors:  R S GRIFFITH
Journal:  Antibiotic Med Clin Ther (New York)       Date:  1960-02

3.  Studies on the distribution and fate of S35-labelled benzylpenicillin in the body.

Authors:  S ULLBERG
Journal:  Acta Radiol Suppl       Date:  1954

4.  Bactericidal activity and pharmacology of flucloxacillin.

Authors:  M G Bergeron; J L Brusch; M Barza; L Weinstein
Journal:  Am J Med Sci       Date:  1976 Jan-Feb       Impact factor: 2.378

5.  Antimicrobial activity and human pharmacology of amoxicillin.

Authors:  H C Neu
Journal:  J Infect Dis       Date:  1974-06       Impact factor: 5.226

Review 6.  Guide to drug usage in adult patients with impaired renal function. A supplement.

Authors:  W M Bennett; I Singer; C H Coggins
Journal:  JAMA       Date:  1973-02-26       Impact factor: 56.272

7.  Antibiotic penetration of the brain. A comparative study.

Authors:  P W Kramer; R S Griffith; R L Campbell
Journal:  J Neurosurg       Date:  1969-09       Impact factor: 5.115

Review 8.  Methicillin: critical appraisal after a decade of experience.

Authors:  D N Gilbert; J P Sanford
Journal:  Med Clin North Am       Date:  1970-09       Impact factor: 5.456

9.  Intrarenal distribution of ampicillin in the normal and diseased human kidney.

Authors:  A Whelton; D G Sapir; G G Carter; M A Garth; W G Walker
Journal:  J Infect Dis       Date:  1972-05       Impact factor: 5.226

Review 10.  Semisynthetic penicillins.

Authors:  G N Rolinson; R Sutherland
Journal:  Adv Pharmacol Chemother       Date:  1973
View more
  26 in total

Review 1.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

2.  Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.

Authors:  N Patel; M H Scheetz; G L Drusano; T P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2009-10-26       Impact factor: 5.191

3.  Evaluation of three newer methods for investigating protein interactions of penicillin G.

Authors:  L R Peterson; D N Gerding; H H Zinneman; B M Moore
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

4.  The effects of posture on the pharmacokinetics of intramuscular benzylpenicillin.

Authors:  R H Rumble; M S Roberts; A R Scott
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  High-dose continuous oxacillin infusion results in achievement of pharmacokinetics targets in critically ill patients with deep sternal wound infections following cardiac surgery.

Authors:  Nicolas Nesseler; Marie-Clémence Verdier; Yoann Launey; Alexandre Malherbe; Marine Dermu; Caroline Piau; Erwan Flécher; Olivier Tribut; Yannick Mallédant; Philippe Seguin
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

6.  Two-compartment dispersion model for analysis of organ perfusion system of drugs by fast inverse Laplace transform (FILT).

Authors:  Y Yano; K Yamaoka; Y Aoyama; H Tanaka
Journal:  J Pharmacokinet Biopharm       Date:  1989-04

7.  The effect of posture on the pharmacokinetics of intravenous benzylpenicillin.

Authors:  R H Rumble; M S Roberts; A R Scott
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Drug interactions with urate excretion in man.

Authors:  D K Sommers; H S Schoeman
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Pharmacokinetics of bacampicillin compared with those of ampicillin, pivampicillin, and amoxycillin.

Authors:  J Sjövall; L Magni; T Bergan
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

10.  The metabolic disposition of flucloxacillin in patients with impaired kidney function.

Authors:  H H Thijssen; J Wolters
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.